Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2011 April;52(2) > The Journal of Cardiovascular Surgery 2011 April;52(2):225-9

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,179


eTOC

 

REVIEWS  DRUG-ELUTING TECHNOLOGIES: WHERE ARE WE


The Journal of Cardiovascular Surgery 2011 April;52(2):225-9

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Drug-eluting stents above the knee

Minar E.

Department of Angiology, Medical University Vienna, Vienna, Austria


PDF  


There are only very few trials concerning use of drug-eluting stents (DES) in the femoropopliteal segment. While earlier trials using a sirolimus-eluting polymer-coated stent and an everolimus-eluting stent failed to demonstrate improved mid-term patency compared with a bare-metal stent, the recently presented ‑ however still unpublished – data with the Zilver PTX stent using a polymer-free paclitaxel coating are very promising. Before we can make definite conclusions and recommendations, we have to see longer-term follow-up data. A potential future improvement of local drug application for the necessary time span without the disadvantages of permanent stent implantation can be expected by the development of completely bioabsorbable DES.

top of page

Publication History

Cite this article as

Corresponding author e-mail

erich.minar@meduniwien.ac.at